Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/resp.14063 http://scihub22266oqcxt.onion/10.1111/resp.14063 33913200!ä!33913200 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respirology 2021 ; 26 (6): 604-611 Nephropedia Template TP {{tp|p=33913200|t=2021. Contemporary Concise Review 2020: Interstitial lung disease |pdf=|usr=}}{{33913200}} gab.com Text Contemporary Concise Review 2020: Interstitial lung disease JO: Respirology http://www.kidney.de/pget.php?&tw=1&pmid=33913200 #FOAvip The year 2020 was one like no other, as we witnessed the far-reaching impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global pandemic. Yet despite an unprecedented and challenging year, global research in interstitial lung disease (ILD) continued to break new grounds. Research progress has led to an improved understanding in new diagnostic tools and potential biomarkers for ILD. Studies on the role of antifibrotic therapies, newer therapeutic agents, supportive care strategies and the impact of coronavirus disease 2019 (COVID-19) continue to reshape the management landscape of ILD. In this concise review, we aim to summarize the key studies published in 2020, highlighting their impact on the various aspects of ILD. Twit Text FOAVip Contemporary Concise Review 2020: Interstitial lung disease ????Respirology http://www.kidney.de/pget.php?&tw=1&pmid=33913200 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33913200 #FOAvip English Wikipedia <ref>{{Cite pmid|33913200}}</ref> Contemporary Concise Review 2020: Interstitial lung disease #MMPMID33913200 Teoh AKY; Corte TJ Respirology 2021[Jun]; 26 (6): 604-611 PMID33913200show ga The year 2020 was one like no other, as we witnessed the far-reaching impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global pandemic. Yet despite an unprecedented and challenging year, global research in interstitial lung disease (ILD) continued to break new grounds. Research progress has led to an improved understanding in new diagnostic tools and potential biomarkers for ILD. Studies on the role of antifibrotic therapies, newer therapeutic agents, supportive care strategies and the impact of coronavirus disease 2019 (COVID-19) continue to reshape the management landscape of ILD. In this concise review, we aim to summarize the key studies published in 2020, highlighting their impact on the various aspects of ILD. |*COVID-19/complications[MESH] |Animals[MESH] |Biomarkers[MESH] |Humans[MESH] |Lung Diseases, Interstitial/complications/*diagnosis/*drug therapy[MESH] |Phenotype[MESH]Contemporary Concise Review 2020: Interstitial lung disease (epmc).pdf DeepDyve Pubget Overpricing